ACE and acute kidney injury: On the other hand, serum potassium < 3.5 mEq/L prior to L-AMB therapy (OR 1.828; 95% CI 1.007–3.319), catecholamine treatment during L-AMB administration (OR 2.442; 95% CI 1.056–5.645), treatment with ACE inhibitors/ARBs (OR 2.511; 95% CI 1.109–5.687) or carbapenem (OR 3.033; 95% CI 1.626–5.654) prior to L-AMB administration, and ≥ 2.93 mg/kg/day of L-AMB dose (OR 2.425; 95% CI 1.319–4.458) were associated with stages 2 and 3 AKI (Tables S3, S4).